- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07575399
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Amgen Call Center
- Telefoonnummer: 866-572-6436
- E-mail: medinfo@amgen.com
Studie Locaties
-
-
-
Ponce, Puerto Rico, 00717
- Werving
- Puerto Rico Medical Research Inc.
-
-
-
-
Alabama
-
Pelham, Alabama, Verenigde Staten, 35124
- Werving
- Cahaba Research, Inc.
-
-
Arizona
-
Chandler, Arizona, Verenigde Staten, 85224
- Werving
- Arizona Clinical Trials
-
Sun City, Arizona, Verenigde Staten, 85351
- Werving
- Epic Medical Research - Sun City
-
Sun City West, Arizona, Verenigde Staten, 85375
- Werving
- Clinical Research Institute of Arizona LLC
-
-
California
-
Chula Vista, California, Verenigde Staten, 91911
- Werving
- Peninsula Research Associates
-
Palm Springs, California, Verenigde Staten, 92262
- Werving
- Desert Oasis Healthcare Medical Group
-
Rialto, California, Verenigde Staten, 92377
- Werving
- Inland Empire Liver Foundation
-
San Diego, California, Verenigde Staten, 92120
- Werving
- Apex Clinical Research
-
Santa Ana, California, Verenigde Staten, 92701
- Werving
- Southern California Clinical Research
-
-
Florida
-
Gainesville, Florida, Verenigde Staten, 32610
- Werving
- University of Florida Department of Medicine
-
Hialeah, Florida, Verenigde Staten, 33012
- Werving
- Aga Clinical Trials
-
Margate, Florida, Verenigde Staten, 33063
- Werving
- South Florida Clinical Research
-
Miami, Florida, Verenigde Staten, 33165
- Werving
- New Horizon Research Center
-
Miami, Florida, Verenigde Staten, 33173
- Beëindigd
- Research Institute of South Florida
-
Mt. Dora, Florida, Verenigde Staten, 32757
- Werving
- Adult Medicine of Lake County
-
Orlando, Florida, Verenigde Staten, 32825
- Werving
- Florida Institute for Clinical Research
-
Orlando, Florida, Verenigde Staten, 32801
- Beëindigd
- Clinical Neuroscience Solutions
-
Port Orange, Florida, Verenigde Staten, 32127
- Werving
- Progressive Medical Research
-
The Villages, Florida, Verenigde Staten, 32162
- Werving
- Charter Research - The Villages
-
-
Georgia
-
Canton, Georgia, Verenigde Staten, 30114
- Werving
- East Coast Institute for Research
-
Columbus, Georgia, Verenigde Staten, 31904
- Werving
- Columbus Research Foundation
-
Johns Creek, Georgia, Verenigde Staten, 30024
- Werving
- Nsc Research
-
Union City, Georgia, Verenigde Staten, 30291
- Werving
- Rophe Adult and Pediatric Medicine/Sky Clinical Research Network Group
-
Woodstock, Georgia, Verenigde Staten, 30189
- Werving
- North Georgia Clinical Research
-
-
Hawaii
-
Kapolei, Hawaii, Verenigde Staten, 96707
- Werving
- Mel A. Ona, M.D., Incorporated
-
-
Idaho
-
Meridian, Idaho, Verenigde Staten, 83646
- Werving
- Solaris Clinical Research
-
-
Illinois
-
Skokie, Illinois, Verenigde Staten, 60077
- Werving
- Endeavor Health
-
Springfield, Illinois, Verenigde Staten, 62704
- Werving
- Central Illinois Diabetes and Clinical Research, a Division of Prairie Education and Research Cooper
-
-
Kansas
-
Lenexa, Kansas, Verenigde Staten, 66219
- Werving
- Johnson County Clinical Trials
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70808
- Werving
- Pennington Biomedical Research Center
-
-
Michigan
-
Southfield, Michigan, Verenigde Staten, 48034
- Werving
- Great Lakes Research Institute
-
Troy, Michigan, Verenigde Staten, 48098
- Werving
- Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division
-
-
Mississippi
-
Ridgeland, Mississippi, Verenigde Staten, 39157
- Werving
- Sky Integrative Medical Center
-
-
Montana
-
Missoula, Montana, Verenigde Staten, 59808
- Werving
- Montana Medical Research
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89109
- Werving
- Excel Clinical Research
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Werving
- Icahn School of Medicine at Mount Sinai
-
Rochester, New York, Verenigde Staten, 14609
- Werving
- Rochester Clinical Research
-
-
North Carolina
-
Morehead City, North Carolina, Verenigde Staten, 28557
- Werving
- Centricity Research Morehead City Specialty
-
Raleigh, North Carolina, Verenigde Staten, 27609
- Werving
- Accellacare of Raleigh
-
Wilmington, North Carolina, Verenigde Staten, 28401
- Werving
- Accellacare Research of Wilmington
-
-
Oklahoma
-
Chickasha, Oklahoma, Verenigde Staten, 73018
- Werving
- Epic Medical Research - Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73112
- Werving
- Lynn Health Science Institute
-
-
Pennsylvania
-
Beaver, Pennsylvania, Verenigde Staten, 15009
- Werving
- Heritage Valley Multispecialty Group Inc
-
Duncansville, Pennsylvania, Verenigde Staten, 16635
- Werving
- Altoona Center for Clinical Research
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78757
- Werving
- Pinnacle Clinical Research Georgetown
-
DeSoto, Texas, Verenigde Staten, 75115
- Werving
- Epic Medical Research - DeSoto
-
Edinburg, Texas, Verenigde Staten, 78539
- Beëindigd
- South Texas Research Institute
-
Houston, Texas, Verenigde Staten, 77043
- Werving
- Biopharma Informatic, LLC
-
Houston, Texas, Verenigde Staten, 77089
- Werving
- Research Physicians Network, LLC
-
Houston, Texas, Verenigde Staten, 77040
- Werving
- JCCT- Juno Northwest Houston
-
McAllen, Texas, Verenigde Staten, 78503
- Werving
- Biopharma Informatic-McAllen
-
McKinney, Texas, Verenigde Staten, 75071
- Werving
- Texas Institute of Cardiology
-
North Richland Hills, Texas, Verenigde Staten, 76180
- Werving
- North Hills Medical Research
-
San Antonio, Texas, Verenigde Staten, 78215
- Werving
- American Research Corporation
-
San Antonio, Texas, Verenigde Staten, 78230
- Werving
- VIP Trials
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- Gastroenterology Clinic of San Antonio PA
-
Tomball, Texas, Verenigde Staten, 77375
- Werving
- Northwest Houston Heart Center
-
-
Washington
-
Redmond, Washington, Verenigde Staten, 98052
- Werving
- Eastside Research Associates Health Research
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Body Mass Index (BMI) ≥ 25 at screening.
- Weight loss of ≥ 10% on weekly GLP-1 RA.
- Stable body weight.
- Stable dose of GLP-1RA.
- Stable gastrointestinal (GI) tolerability.
- Contraception for females.
- Willingness to follow trial procedures for the duration of the trial.
Exclusion Criteria:
- Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
- Previous or planned surgical, endoscopic or device-based treatment for obesity.
- History of malignancy.
- Type 1/Type 2 diabetes mellitus (DM).
- Family or personal history of medullary thyroid cancer.
- Previous participation in a Maridebart Cafraglutide trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: MariTide Arm 1
Participants will receive maridebart cafraglutide dosing schedule 1 during the treatment period. |
Maridebart cafraglutide will be administered via subcutaneous (SC) injection.
Andere namen:
|
|
Experimenteel: MariTide Arm 2
Participants will receive maridebart cafraglutide dosing schedule 2 during the treatment period. |
Maridebart cafraglutide will be administered via subcutaneous (SC) injection.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Percent Change from Baseline in Body Weight at Week 68
Tijdsspanne: Week 68
|
Week 68
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Percent Change in Body Weight Prior to the Start of Weekly GLP-1RA at Week 68
Tijdsspanne: Week 68
|
Week 68
|
|
Percentage of Participants Maintaining ≥ 80% of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
Tijdsspanne: Week 68
|
Week 68
|
|
Percent Maintenance of the Body Weight Reduction Achieved with Prior Weekly GLP-1RA Treatment at Week 68
Tijdsspanne: Week 68
|
Week 68
|
|
Plasma Concentration of Maridebart Cafraglutide at Week 68
Tijdsspanne: Week 68
|
Week 68
|
|
Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events
Tijdsspanne: Up to 84 weeks
|
Up to 84 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: MD, Amgen
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 20250036
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD-tijdsbestek voor delen
Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.
IPD-toegangscriteria voor delen
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .